$27.01
0.55% day before yesterday
Nasdaq, Jan 02, 10:04 pm CET
ISIN
US15117B1035
Symbol
CLDX

Celldex Therapeutics, Inc. Stock price

$27.01
+0.34 1.27% 1M
+4.90 22.16% 6M
-0.15 0.55% YTD
+1.22 4.73% 1Y
-17.56 39.40% 3Y
+7.91 41.41% 5Y
-197.84 87.99% 10Y
-1.19 4.22% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-0.15 0.55%
ISIN
US15117B1035
Symbol
CLDX
Industry

Key metrics

Basic
Market capitalization
$1.8b
Enterprise Value
$1.2b
Net debt
positive
Cash
$583.2m
Shares outstanding
66.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
690.3 | 676.0
EV/Sales
466.0 | 456.3
EV/FCF
negative
P/B
3.0
Financial Health
Equity Ratio
94.3%
Return on Equity
-21.1%
ROCE
-42.6%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$2.6m | $2.7m
EBITDA
$-252.9m | $-265.3m
EBIT
$-256.2m | $-275.6m
Net Income
$-224.5m | $-247.5m
Free Cash Flow
$-181.7m
Growth (TTM | estimate)
Revenue
-74.0% | -62.2%
EBITDA
-37.8% | -38.3%
EBIT
-37.3% | -41.3%
Net Income
-45.7% | -56.8%
Free Cash Flow
-13.8%
Margin (TTM | estimate)
Gross
-
EBITDA
-9,725.3% | -9,992.8%
EBIT
-9,855.4%
Net
-8,635.9% | -9,323.1%
Free Cash Flow
-6,987.3%
More
EPS
$-3.4
FCF per Share
$-2.7
Short interest
12.2%
Employees
186
Rev per Employee
$40.0k
Show more

Is Celldex Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Celldex Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

22 Analysts have issued a Celldex Therapeutics, Inc. forecast:

18x Buy
82%
3x Hold
14%
1x Sell
5%

Analyst Opinions

22 Analysts have issued a Celldex Therapeutics, Inc. forecast:

Buy
82%
Hold
14%
Sell
5%

Financial data from Celldex Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
2.60 2.60
74% 74%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 42 42
14% 14%
1,622%
- Research and Development Expense 217 217
47% 47%
8,334%
-253 -253
38% 38%
-9,725%
- Depreciation and Amortization 3.38 3.38
8% 8%
130%
EBIT (Operating Income) EBIT -256 -256
37% 37%
-9,855%
Net Profit -225 -225
46% 46%
-8,636%

In millions USD.

Don't miss a Thing! We will send you all news about Celldex Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Celldex Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
25 days ago
HAMPTON, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the initiation of its global Phase 3 trial (EMBARQ-ColdU and SD) designed to establish the efficacy and safety of barzolvolimab in adult patients with cold urticaria (ColdU) and symptomatic dermographism (SD) who remain symptomatic despite H1 antihistamine treatment. ColdU and SD are characterized by the occu...
Neutral
GlobeNewsWire
about 2 months ago
HAMPTON, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ: CLDX) today announced the appointment of Teri Lawver as Senior Vice President, Chief Commercial Officer. Ms. Lawver is an accomplished global healthcare executive with 30 years of strategic, commercial launch and operating P&L leadership across the biopharmaceutical, medical device and consumer health technology sectors. Ms. Lawv...
Neutral
GlobeNewsWire
about 2 months ago
HAMPTON, N.J., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at the following upcoming investor conferences:
More Celldex Therapeutics, Inc. News

Company Profile

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Head office United States
CEO Anthony Marucci
Employees 186
Founded 1983
Website celldex.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today